Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2019

Feb 26, 2019

29777_dirs_2019-02-26_756bf8b5-a3a8-495c-99ea-a1a7106ea124.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-02-22

Reporting Person: PEDERSON MICHAEL J (Senior Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-02-22 Common shares without par value A 13833 Acquired 85751 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-02-22 Option (right to buy) $75.90 A 72513 Acquired 2029-02-21 Common shares (72513) Direct

Footnotes

F1: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,171 on February 22, 2020, 24,171 on February 22, 2021, and 24,171 on February 22, 2022.